The content on this site is intended for healthcare professionals only
Dr Luis Raez shares his overview of the WCLC World Conference on Lung Cancer 2020 meeting.
He highlights some of the key presentations from the meeting, beginning with the CodeBreak 100 trial evaluating the agent sotorasib which targets the KRAS G12C mutation.
Dr Raez also covers the TALENT study, which evaluates the effectiveness of low-dose computed tomography (LDCT) screening in non smokers, and also the LCMC3 study into neoadjuvant atezolizumab prior to lung cancer surgery.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Choosing Wisely in radiology Tanzania
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Choosing Wisely to mitigate financial toxicity in cancer care in Africa
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML
